NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Receives Average Rating of “Hold” from Analysts

Shares of NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) have been assigned an average rating of “Hold” from the five brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $7.3333.

A number of research firms recently weighed in on NMTC. Maxim Group set a $5.00 target price on NeuroOne Medical Technologies and gave the stock a “buy” rating in a report on Friday, August 14th. Weiss Ratings downgraded NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Finally, LADENBURG THALM/SH SH lifted their price objective on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th.

Insider Activity

In other news, Director Mark Christianson sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $3.18, for a total transaction of $31,800.00. Following the completion of the sale, the director owned 20,692 shares in the company, valued at approximately $65,800.56. This trade represents a 32.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 11.80% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NMTC. Susquehanna International Group LLP acquired a new stake in NeuroOne Medical Technologies during the second quarter worth approximately $41,000. Bard Associates Inc. acquired a new position in shares of NeuroOne Medical Technologies in the second quarter valued at approximately $929,000. BlackRock Inc. acquired a new position in shares of NeuroOne Medical Technologies in the second quarter valued at approximately $76,000. XTX Topco Ltd increased its stake in shares of NeuroOne Medical Technologies by 321.1% during the fourth quarter. XTX Topco Ltd now owns 85,454 shares of the company’s stock worth $65,000 after purchasing an additional 65,163 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in NeuroOne Medical Technologies during the 4th quarter worth approximately $36,000. 16.07% of the stock is owned by institutional investors.

NeuroOne Medical Technologies Stock Performance

Shares of NASDAQ:NMTC opened at $2.03 on Monday. NeuroOne Medical Technologies has a 52-week low of $1.42 and a 52-week high of $6.96. The company has a market capitalization of $18.49 million, a P/E ratio of -2.14 and a beta of 0.61. The company has a 50-day simple moving average of $2.41 and a 200 day simple moving average of $3.66.

NeuroOne Medical Technologies (NASDAQ:NMTC) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.07). NeuroOne Medical Technologies had a negative return on equity of 128.12% and a negative net margin of 71.50%.The business had revenue of $1.97 million for the quarter, compared to analyst estimates of $2.17 million. As a group, equities analysts forecast that NeuroOne Medical Technologies will post -0.39 earnings per share for the current year.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.